Esteve CDMO, the Contract Development and Manufacturing Organization (CDMO) business of the Catalan pharmaceutical company, will invest 80 million dollars, equivalent to a little over 71 million euros, in a new production plant in China. This was announced in a statement this Wednesday, in which they detail that the move will serve to undertake the "relocation, expansion, and modernization" of its operations in the Asian giant.

The National Commission of Markets and Competition (CNMC) has decided to advance the acquisition of Esteve Teijin Healthcare by Oximesa to Phase 2—a more in-depth analysis in which parties considered affected can submit objections. According to the agency chaired by Cani Fernández, the transaction could lead to excessive dominance of the home respiratory therapy market.